首页> 外文期刊>Cardiovascular Intervention and Therapeutics >Initial clinical experience with distal embolic protection using “Filtrap”, a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention
【24h】

Initial clinical experience with distal embolic protection using “Filtrap”, a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention

机译:在经皮冠状动脉介入治疗患者中使用“ Filtrap”(一种具有自膨胀螺旋篮的新型过滤器设备)进行远端栓塞保护的初步临床经验

获取原文
获取原文并翻译 | 示例
       

摘要

We developed a new filter-type distal protection guide wire, Filtrap, that uses a polyurethane filter with 1834 100-μm micropores covering the distal half of a spindle-shaped spiral Ni–Ti basket. The basket is 5 mm in diameter, self-expandable, and is mounted at the distal end of the system. This study aimed to assess the usefulness and safety of Filtrap during percutaneous coronary intervention (PCI). Early angiographic and in-hospital outcomes were reviewed in 14 patients, including 9 acute coronary syndrome patients, treated with Filtrap during PCI. All lesions were located in native coronary arteries but one was located in a saphenous vein graft. The Filtrap was successfully delivered and deployed distal to the lesion in 13 of 14 patients (93%). All PCI procedures including stent implantation were successfully completed except for 2 AMI patients, who ended up with Thrombolysis in Myocardial Infarction (TIMI) 2 coronary flow. One of these 2 patients had a distal embolization which occurred after thrombectomy before Filtrap insertion. The mean time of device insertion was 9.4 ± 3.2 min. Five patients showed transient no-reflow that was completely restored immediately with removal of the device. Embolic debris was entrapped in 8 (62%) of these cases. All patients were free from in-hospital events except for one patient with a large anterior acute myocardial infarction who received an emergency surgery due to a free wall cardiac rupture. These results suggest that the Filtrap is a practical and safe device for embolic protection during PCI.
机译:我们开发了一种新型的过滤器型远端保护导丝Filtrap,该导丝使用具有1834个100μm微孔的聚氨酯过滤器覆盖了纺锤状螺旋镍钛网的远端。篮的直径为5毫米,可自我膨胀,并安装在系统的远端。这项研究旨在评估Filtrap在经皮冠状动脉介入治疗(PCI)期间的有效性和安全性。回顾了14例患者的早期血管造影和住院结局,包括9例急性冠脉综合征患者,在PCI期间接受Filtrap治疗。所有病变均位于天然冠状动脉,但一个位于隐静脉移植物中。 Filtrap已成功交付,并在14例患者中的13例中(93%)部署到病变远端。除2名AMI患者外,所有PCI手术(包括支架植入术)均已成功完成,最终以心肌梗死(TIMI)2冠状动脉血栓溶解术结束。这2例患者中有1例发生了远端栓塞,该栓塞是在Filtrap插入前的血栓切除术后发生的。插入设备的平均时间为9.4±3.2分钟。五名患者表现出短暂的无复流,并且在移除设备后立即完全恢复。其中8例(62%)夹有栓塞碎屑。所有患者均未发生院内事件,只有一名患有大面积急性前壁心肌梗死的患者因游离壁心脏破裂而接受了急诊手术。这些结果表明,Filtrap是一种用于PCI期间栓塞保护的实用且安全的设备。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号